Phase I-II Trial Committee

  • Close interaction with biology/ pathology and NRSTS committee to enhance translational research and trial development
  • Organisation of joint workshops with the biology committee to work on targets/ drugs of interest in RMS and going forward also NRSTS and to focus on topics requiring improvement in models and expertise to benefit patients with RMS (examples: workshops 1 and 2 in 11/2020 and 4/2021 on targets and drugs of interest; workshop 3: maintenance therapy in RMS), aim for future workshops with the NRSTS committee
  • To identify targets/ drugs of interest and consider taking them forward in early Phase trials (-> interaction with ITCC)
  • To provide the update on Early Phase trials (Pharma and academia) available for RMS and NRSTS patients on international level within EpSSG countries and beyond
  • To support the EpSSG meeting programmes from a novel agent/ drug development point of view with invitation of pharma for targets of special interest to educational sessions (eg invitation of Adaptimmune to present on their immunotherapy afamitresgene auoleucel targeting MAGE-4 in HLA-A*A02 context).
  • To discuss and increase translational biomarker work in our EpSSG driven clinical trials (example: incorporation of molecular and imaging biomarker analysis within the randomised relapse study within FaR-RMS including regorafenib as targeted agent)
  • To define high-risk patient groups and develop better treatment strategies for them (examples: ongoing project on refractory RMS and MYOD1 mutated RMS
  • To publish on these topics and on completed trials (eg VIT study, review on volasertib.

Contact information chair

Susanne Gatz
Associate Professor in Paediatric Oncology and
Honorary Consultant in Paediatric Oncology
University of Birmingham/ Birmingham Children’s Hospital, UK
Current Members
Susanne GatzUKInstitute of Cancer and Genomic Sciences, University of Birmingham
Michela CasanovaItalyPediatric Oncology Unit, Istituto Nazionale Tumori Milano
Julia ChisholmUKThe Institute of Cancer Research, The Royal Marsden
Anne-Sophie DefachellesFrancePediatric Unit, Centre Oscar Lambret, Lille
Veronique Minard ColinFranceHospital Gustave Roussy, Villejuif
Raquel Hladun AlvaroSpainDepartment of Pediatric Oncohematology, Hospital Universitari Vall d´Hebron, Barcelona
Hans MerksNetherlandsPrincess Máxima Center for pediatric oncology, Utrecht
Max van NoeselNetherlandsPrincess Máxima Center for pediatric oncology, Utrecht
Willemijn BreunisSwitzerlandUniversity Children's Hospital, Zurich
Pablo BerlangaFranceHospital Gustave Roussy, Villejuif
Ajla WastiUKThe Royal Marsden NHS Foundation Trust, London